Related Experiment Videos
Leukotrienes, fish-oil, and asthma
1Department of Rheumatology, Brigham and Women's Hospital, Boston, Massachusetts 02115.
Allergy Proceedings : the Official Journal of Regional and State Allergy Societies
|May 1, 1994
Summary
Marine fish oils containing eicosapentaenoic acid (EPA) and docosahexaenoic acid (DCHA) can limit leukotriene synthesis. These fatty acids may help manage inflammatory disorders like allergic asthma by reducing pro-inflammatory mediators.
Area of Science:
- Biochemistry
- Immunology
- Pharmacology
Background:
- Leukotrienes, metabolized from arachidonic acid, are implicated in inflammatory disorders such as chronic allergic asthma.
- Arachidonic acid is released from membrane phospholipids during cell activation, initiating inflammatory pathways.
Purpose of the Study:
- To investigate the role of marine fish oil fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DCHA), in modulating leukotriene synthesis and inflammatory mediator production.
Main Methods:
- The study focuses on the biochemical mechanisms by which EPA and DCHA interfere with arachidonic acid metabolism.
- Investigated the inhibition of leukotriene synthesis and the reduction of platelet-activating factor (PAF) production.
Main Results:
- EPA and DCHA act as alternative substrate fatty acids, limiting leukotriene synthesis and biological activities.
- Both EPA and DCHA were found to inhibit the cyclooxygenase pathway conversion of arachidonic acid to prostanoid metabolites.
- A reduction in platelet-activating factor (PAF) production was observed with EPA and DCHA supplementation.
Conclusions:
- Marine fish oil components EPA and DCHA demonstrate potential in limiting key inflammatory mediators.
- These findings suggest a therapeutic role for EPA and DCHA in managing inflammatory conditions, including allergic asthma.